💰钛媒体•Stalecollected in 61m
Isomorphic Labs Secures Record AI Drug Funding
💡A massive funding milestone proving the commercial viability of AI-driven drug discovery.
⚡ 30-Second TL;DR
What Changed
Record-breaking 14.3 billion RMB funding for AI drug discovery
Why It Matters
Signals a major shift in capital allocation towards AI-native pharmaceutical companies, potentially accelerating drug development timelines.
What To Do Next
Monitor the research papers published by Isomorphic Labs to understand their approach to protein folding and drug design.
Who should care:Researchers & Academics
Key Points
- •Record-breaking 14.3 billion RMB funding for AI drug discovery
- •Focus on paradigm shift in pharmaceutical R&D
- •Leveraging AI for complex biological data analysis
🧠 Deep Insight
Web-grounded analysis with 19 cited sources.
🔑 Enhanced Key Takeaways
- •The record funding is a $2.1 billion Series B round, announced on May 12, 2026, led by Thrive Capital with participation from existing backers Alphabet and GV, and new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
- •Isomorphic Labs' proprietary AI drug design engine, IsoDDE, extends beyond protein structure prediction to actively generate novel molecules from scratch and predict binding affinities with superior accuracy and speed compared to traditional methods.
- •A significant milestone was achieved in January 2026 with the FDA clearance of ISM8969, one of Isomorphic Labs' AI-designed drugs, for human clinical trials.
- •The company utilizes Google Cloud's AI Hypercomputer, including TPUs and GPUs orchestrated by Google Kubernetes Engine, to provide scalable infrastructure that accelerates inference workloads by up to 50%.
- •Isomorphic Labs has established strategic collaborations with major pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson, alongside developing an internal drug candidate pipeline focused on oncology and immunology.
🛠️ Technical Deep Dive
- Isomorphic Labs' core technology is its unified AI drug design engine, IsoDDE, which builds upon and extends the capabilities of AlphaFold technology.
- AlphaFold 3, released in May 2024 in collaboration with Google DeepMind, can predict the structures and interactions of all of life's molecules, including proteins, DNA, RNA, ligands, and antibodies, with high accuracy.
- IsoDDE goes beyond structure prediction, focusing on designing new molecules from first principles and targeting disease mechanisms that have been challenging for traditional medicinal chemistry.
- The engine demonstrates predictive accuracy for small molecule binding-affinities, outperforming physics-based methods in speed and cost efficiency, and can identify new binding pockets on target proteins using only amino acid sequences.
- Isomorphic Labs' infrastructure leverages Google Cloud's AI Hypercomputer, managing fleets of TPUs and GPUs orchestrated by Google Kubernetes Engine to achieve rapid scalability and accelerate inference workflows by up to 50%.
- The AI models are designed to be generalizable, working across multiple therapeutic areas and drug modalities (e.g., small molecules, biologics) in an end-to-end, target and disease-agnostic manner.
- The company maintains a unique, curated collection of life science data, referred to as a 'dataverse,' which powers its research environment and supports massive volumes of in-silico experiments.
🔮 Future ImplicationsAI analysis grounded in cited sources
AI-designed drugs will reach clinical success faster and at a lower cost, disrupting traditional pharmaceutical R&D timelines.
Isomorphic Labs' AI-first approach, exemplified by its IsoDDE engine and the rapid progression of an AI-designed drug (ISM8969) to human clinical trials, aims to significantly compress the traditional drug discovery timeline and reduce associated costs, setting a new industry benchmark.
The pharmaceutical industry will see a broader shift towards AI-first drug discovery platforms, increasing competition and innovation.
The substantial investment in Isomorphic Labs and its early clinical validation will pressure traditional pharmaceutical companies to further integrate AI, potentially making AI a 'first pass' for drug discovery with lab work serving as confirmation, thereby accelerating industry-wide innovation.
⏳ Timeline
2021-02
Isomorphic Labs incorporated.
2021-11
Isomorphic Labs officially announced by Alphabet as a DeepMind spin-off, with Demis Hassabis as CEO.
2024-01
Strategic research collaborations announced with Novartis and Eli Lilly.
2024-05
Google DeepMind and Isomorphic Labs release AlphaFold 3.
2025-03
Raised $600 million in its first external funding round (Series A) led by Thrive Capital.
2026-01
AI-designed drug, ISM8969, receives FDA clearance for human clinical trials.
2026-02
Announced its Drug Design Engine (IsoDDE), an evolution beyond AlphaFold 3.
2026-05
Secured $2.1 billion in Series B funding.
📎 Sources (19)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 钛媒体 ↗